Side-by-side · Research reference
P21vsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BHuman-MechanisticAUTO-DRAFTED12/39 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
P21
Semax
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
—
—
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
P21
Semax
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Human-mechanistic + Russian clinicalKaplan 2017
Duration
Not specified
10–14 day cycles, repeated PRN
Route
Presumed subcutaneous or intraperitoneal (animal studies)
—
Frequency
—
2–3× per day during cognitive demand
Lower / starter dose
—
100 mcg / dose
Reconstitution
—
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
—
Morning + early afternoon
Half-life
—
Short plasma; CNS effect lasts ~3–6 hr
04Side Effects & Safety
Parameter
P21
Semax
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Headache
—
Uncommon, transient
Long-term safety
—
Limited Western RCT data
Pregnancy / OB
—
Avoid
Absolute Contraindications
P21
- ·Use in humans not validated
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
P21
Semax
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
—
Morning + early afternoon. Avoid evening (sleep disruption).
4. Storage
—
Refrigerate after reconstitution; light-protected.
5. Caveat
—
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
P21
— no documented stacks
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation